Skip to content

Neuroblastoma Susceptibility To 3 C2751681

Published: July 22, 2026Updated: August 20, 2026

A hereditary risk factor for developing neuroblastoma. Families may benefit from genetic counseling and surveillance for affected children.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Spinal cord compression

Abdominal mass

(gastrointestinal)

Generalized symptoms

(oncologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Bone pain

(musculoskeletal)

Hypertension

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Comprehensive Tumor Surveillance

Structured surveillance program including abdominal imaging, metaiodobenzylguanidine (MIBG) scanning, and regular physical examinations tailored to susceptibility gene profile.

monitoring
2

Evidence-based pharmacological treatment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Immunomodulatory Therapy

Immunological support using agents that enhance immune surveillance mechanisms in individuals with identified immune-related susceptibility pathways.

medication

Additional treatment options

Biopsy and Genetic Confirmation

Tissue sampling procedures to confirm diagnosis and perform comprehensive genomic profiling when surveillance detects abnormalities requiring intervention.

procedure

Antioxidant-Rich Nutritional Support

Dietary optimization with antioxidant-rich foods including fruits, vegetables, and cruciferous vegetables that may support cellular protection mechanisms.

dietary

Mind-Body Stress Reduction

Complementary approaches including meditation, yoga, and mindfulness practices to reduce stress-related immunosuppression that may affect tumor surveillance.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Neuroblastoma Susceptibility To 3 C2751681?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Neuroblastoma Susceptibility To 3 C2751681. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy